Until April 16, 2019, patients were required to undergo an ultrasound examination prior to the prescription of Mifegymiso. The ultrasound was used to determine the gestational age and ensure the pregnancy was not ectopic. However, this requirement resulted in delays, which hampered the applicability of the drug. Instead of requiring an ultrasound, the new protocol allowed the prescriber to use their medical judgment in determining whether the patient is suited for Mifegymiso.